What is Chronic Lymphocytic Leukemia (CLL)?
According to Dr. Jacqueline Barrientos, Chronic Lymphocytic Leukemia (CLL) is the most common chronic leukemia in America and Europe with 15,000 new cases in the US every year. She explains that the disease has two parts: the “leukemia” component and the “lymphoma” component.
The difference between a leukemia and lymphoma is that leukemia sees cancer cells circulating in the blood. Lymphoma cells tend to show up in lymph nodes or organs.
CLL cells live and proliferate by going to the lymph nodes to grow. Once they grow in the lymph nodes, they go out into the blood. As the medical field advances, so do treatment options. CLL is just one cancer of many that is making some big leaps in research recently.
Read on to learn about the difference between CLL and ALL, how CLL is diagnosed, what to look our for, and the most important thing you can do for yourself during treatment.
What’s the difference between CLL and ALL?
According to Dr. Tim Fenske, M.D., “The ‘C’ in CLL stands for chronic, whereas the ‘A’ in ALL stands for acute. You have acute leukemias and chronic leukemias. Acute leukemias come on pretty quickly. Typically, there’s a shorter lead up. The patient usually won’t have had months or years of symptoms. Usually what happens is they start getting sick and somebody eventually checks some blood counts, and they’re way outside of the normal range. “
“With chronic leukemias, people can have an elevated white blood cell count for three, four or even 10 times the normal level for years and not have to have it treated because it’s a very slow moving disease.”
“Acute leukemias are fast moving. We would almost never delay treatment for acute leukemia. You see it, and you treat it.”
How is CLL diagnosed?
“For the most part, it’s found by doing a routine blood check by an internist. Usually, they first notice that the white blood cell count is a little high, so they send the patient for a referral,” Barrientos says.
“Sometimes, people might be shaving or washing their face and notice they have an enlarged lymph node. In that case, we’d do a biopsy, and the biopsy would show leukemia.“
This means that CLL can present in your blood, your lymph nodes, or both.
Dr. Barrientos explains that there are three major categories of patients.
One-third won’t develop symptoms, but they will be affected in the sense that they will be at a high risk for infections and malignancies.
Another third won’t need treatment right away, but they usually start up to three years after diagnosis.
The last third of patients will be showing problematic symptoms like anemia, low platelets, or painful, enlarged lymph nodes. They will require treatment immediately. In these cases, not only is their age and medical history taken into account, but also things like their lifestyle and how the patient will tolerate the prescribed treatment.
What are some things to look out for?
“There’s a marker called 17p deletion. That’s a very bad mutation. It not only tells you that the disease will be more aggressive, but it also does not respond to chemotherapy,” Dr. Barrientos says.
A very small number of patients have the 17p deletion mutation when they are diagnosed, but it can develop over time. It’s important to know if you have this marker because it will tell you what kinds of treatment will and will not work for you.
“Another important marker is called IgHV mutation status,” she says. “As a patient, I would want to know my status. You can be either mutated or unmutated. Mutated patients usually have a very slow-growing disease, and on average, they don’t require therapy for the first eight years after their diagnosis.
If you are not mutated, most people require therapy within the first three years. It’s more aggressive. When treated with chemo, these are the patients that will have a shorter time in remission compared to mutated patients.”
It’s helpful to know where you stand. Knowing which markers you have narrows down the guesswork. Make sure your doctor has the means to run these kinds of tests. That way, you get the most accurate treatment plan possible. If you doctor can’t find out this information for you, maybe try seeing a specialist who can.
What’s the most important thing patients can do for themselves during treatment?
“The field is changing so quickly that I think the most important thing you can do is to be an advocate for yourself.
It’s very important to educate yourself so you know if something doesn’t feel right. Go get the second and third opinions.” Dr. Barrientos says.
People react to diagnoses differently. Some want all the information so they can research because they’re scared. Others just want to let the doctors do their job and not be told anything because they’re scared.
Dr. Rafael Fonseca is a myeloma specialist and shows that doctors across all specialties generally agree that an informed patient is the best kind.
“I would rather see a patient in my office who knows a lot about their disease where we can spend our time talking about specific aspects of treatment rather than waste their time having to go back to the basics with them. It’s a better return on investment for you,” Dr. Fonseca says.
Read Chronic Lymphocytic Leukemia (CLL) Stories
1st Symptoms: Lump in back of neck that got bigger in a couple weeks
Treatment: Targeted therapy - orall pill (Imbruvica), takes 3 pills a night
1st symptoms: No apparent symptoms; went to ER for unrelated shoulder pain
Treatment: Clinical trial, Ibrutinib & Venetoclax
1st symptoms: difficulty swallowing and fatigue
Treatment: Rituxan, Bendamustine, targeted therapy BTK inhibitor (ibrutinib)
1st Symptoms: Slow healing, scalp infection, enlarged lymph nodes
Treatment: Clinical trial of ibrutinib, fludarabine, chlorambucil and rituximab; acalabrutinib
1st symptoms: Tightness, lumps in left side of neck, severe pain in left shoulder, enlarged spleen
Treatment (CLL): 6 cycles of EPOCH, clinical trial for DuoHexabody-CD37
1st symptoms: Out of breath, dizzy, nauseated, tiredness, palpitations
Treatment: Obinutuzumab & venetoclax
1st Symptoms: Nosebleeds (unrelated) led to blood work, revealing high WBCs
Treatment: Clinical trial, Gazyva (obinutuxumab) and steroids, Jakafi (ruxolitinib), Inrebic (fedratinib), Reblozyl (luspatercept)